DocWire News interviews Dr. Joshua Sabari, of the Perlmutter Cancer Center at NYU Langone Health, about recent results of the CHRYSALIS study presented at the ESMO 2020 conference.

The CHRYSALIS study evaluated the patient response rate of the human bispecific antibody amivantamab in combination with an EGFR tyrosine kinase inhibitor lazertinib in patients with non-small cell lung cancer.

Read a press release about the study here.